Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2016
Price : $35 *
At a glance
- Drugs Carteolol/latanoprost (Primary) ; Latanoprost
- Indications Glaucoma; Ocular hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 27 Aug 2015 Status changed from recruiting to completed as ClinicalTrials.gov record.
- 07 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 20 Jun 2014 New trial record